Navegando por Assunto "Neutrophils"

Agora exibindo 1 - 2 de 2

Acesso aberto (Open Access)
Avaliação de neutrófilos circulantes em pacientes com neoplasias mieloproliferativas philadelphia negativas em tratamento quimioterápico
(Universidade Federal do Pará, 2018-06-27) SARGES, Érica dos Santos; RIBEIRO, Carolina Heitmann Mares Azevedo; http://lattes.cnpq.br/3848996822163999; https://orcid.org/ 0000-0002-9457-2733
Myeloproliferative neoplasms (MPNs) are a group of blood cell diseases that arise from a change in the hematopoietic stem cell. The most classic are Polycythemia vera (PV) and Essential thrombocythemia (ET). Negative Ph1 NMPs have a long and relatively benign clinical course but have no cure. Cytoreductive chemotherapy acts not only on erythrocytes and megakaryocytes, but also has its action on leukocytes, specifically neutrophils. One of the therapies employed is Hydroxyurea (HU), which has neutropenia as one of its side effects, studies show that this drug can have direct effects on neutrophils. The identification of possible quantitatively and qualitatively changes of neutrophils under the effects of cytoreductive chemotherapy in patients with negative Ph1 MPNs represents an advance in the understanding of the treatment in these MPNs. Hemogram and leukogram are part of the treatment follow-up protocol. In order to qualitatively evaluate some functions, the neutrophils were sensitized with zymosan, thus stimulating the phagocytosis, in relation to the metabolism, the cytochemical test of spontaneous reduction of nitroblue tetrazolium (NBT), besides quantification of myeloperoxidase (MPO) through flow cytometry. In this study, all methodologies previously cited for quantitative and qualitative evaluation were performed on blood samples from 46 patients (PV = 17; ET = 29). The patients with PV had lower IF than the control group, with p = 0.0002 (2.83 ± 1.28, 3.83 ± 1.38, respectively). The same was observed in the patients with ET who presented lower index than the control subjects with p = 0.0002 (2.85 ± 1.34, 3.83 ± 1.38 respectively). Our results showed that there was no difference in the activation of the oxidative metabolism in the NBT reduction test, between the control group and the PV group in HU use, with p = 0.9047 (5 ± 2.7, 2.9 ± 3.5 respectively) and control group with ET group in HU use, presenting p = 0.2870 (5 ± 2.7, 5 ± 6.9 respectively). The MPO test was performed on all patients with NMPs who were undergoing treatment with HU. Our results showed that there was no difference between the control group and the patients in the PV group, with p = 0.8438 (98.47 ± 1.15, 98.54 ± 1.46, respectively). controls and patients with ET, with p = 0.5842 (98.47 ± 1.15, 97.93 ± 3.21 respectively). Patients with PV and ET who used HU presented qualitative changes in neutrophils, in which the use of HU decreased the phagocytic activity of neutrophils in these patients.
Acesso aberto (Open Access)
Avaliação funcional de neutrófilos circulantes em portadores de leucemia mielóide crônica antes e após o início do tratamento com mesilato de imatinibe
(Universidade Federal do Pará, 2019-07-02) DAMASCENO, David Wendell Isacksson; RIBEIRO, Carolina Heitmann Mares Azevedo; http://lattes.cnpq.br/3848996822163999; https://orcid.org/ 0000-0002-9457-2733
Objective: To evaluate neutrophil function in patients with chronic myeloid leukemia (CML) before and after initiation of treatment with imatinib mesylate (MI). Material and Methods: The study included 13 patients diagnosed with CML (new cases), with a mean age of 51 years, of both sexes, selected at the hematology outpatient clinic of the Ophir Loyola Hospital, Belém-PA. In this group three blood samples were taken. The first collection at the time of diagnosis with the untreated patient (Group B1), the second collection after one month of IM treatment (Group B2) and the third collection after four months of treatment (Group B3). The control group (Group A) consisted of 13 healthy volunteers of both sexes. In addition to the blood count and leukogram, the phagocytosis assays and the cytochemical test for spontaneous reduction of nitroazul tetrazolium (NBT) were also performed to evaluate the neutrophil oxidative metabolism. Results: The evaluation of phagocytic function indicated statistical difference when compared Group A with Groups B1, B2 and B3, p = 0.0001. Groups B1, B2 and B3 presented lower phagocytic indices (IFs) with 2.07 ± 0.5; 1.99 ± 0.4 and 1.97 ± 0.6 respectively, compared to Group A with 3.72 ± 0.8. In the oxidative metabolism evaluation there was no statistical difference between group A with groups B1, B2 and B3, p = 0.2997. Discussion: The results showed that untreated patients had lower IF compared to the control group. This means that even if the patient has innumerable cells of the proliferative process, these cells have their functions diminished. Patients treated with MI also had lower IF compared to the control group. Although the number of leukocytes and neutrophils decreased in these patients, the phagocytic capacity of these cells remained decreased. There was no statistical difference regarding the activation of oxidative metabolism in the NBT reduction test. This means that the production of ROS by the NADPH oxidase system does not change independently of MI treatment. Conclusion: There was a reduction in the amount of circulating neutrophils after initiation of IM treatment. The phagocytic function of neutrophils remained decreased after initiation of IM treatment. Neutrophil oxidative metabolism does not change independently of MI treatment. Therefore, additional studies are important to evaluate the exact mechanism of function alteration involved in these patients to allow a better orientation regarding the therapy used.